TG Therapeutics (TGTX) Stock Forecast & Price Target

TG Therapeutics is supported by BRIUMVI’s strong commercial traction, including U.S. market share rising to 8% in 1Q26 from 7% and being the only anti-CD20 to grow U.S. revenues sequentially while Ocrevus and Kesimpta declined. Its fundamental case is reinforced by real-world ENABLE data showing 99.4% relapse-free persistence among switchers, an ARR of 0.011, and durable improvements in satisfaction, convenience, tolerability, and global experience through Week 48. Management also has an operational edge from BRIUMVI’s IV profile, with every-6-month dosing, >60% of the B-cell depleting market remaining IV, and a potential 2027 launch for consolidated dosing that could further support share gains.

TG Therapeutics is a commercial-stage biotech whose investment case depends heavily on BRIUMVI, but the core clinical readout still shows a mixed profile: while ARR improved to 0.08 and 0.09 versus 0.19 and 0.18 for teriflunamide, the disability endpoints were not statistically significant, limiting confidence in durable differentiation. Although MRI lesion reductions were strong, the company’s own valuation framework relies on aggressive assumptions through 2038, a 12% discount rate, and terminal growth of -25%, suggesting the market may be pricing in execution that is far from certain. With value concentrated in Briumvi IV and SC and no other pipeline assets or indications included, any safety issue, weaker-than-expected efficacy, regulatory setback, or heavier commercial competition could materially pressure the thesis.